Aimmune Therapeutics, Inc. (AIMT) Issues Quarterly Earnings Results
Aimmune Therapeutics, Inc. (NASDAQ:AIMT) issued its earnings results on Monday. The biotechnology company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.09, Bloomberg Earnings reports.
Aimmune Therapeutics (NASDAQ AIMT) traded down $0.25 during trading hours on Tuesday, reaching $30.53. The company’s stock had a trading volume of 36,706 shares, compared to its average volume of 744,380. Aimmune Therapeutics has a twelve month low of $15.97 and a twelve month high of $37.50.
In other Aimmune Therapeutics news, insider Douglas T. Sheehy sold 47,425 shares of the business’s stock in a transaction that occurred on Monday, October 23rd. The stock was sold at an average price of $34.44, for a total transaction of $1,633,317.00. Following the sale, the insider now directly owns 34,300 shares of the company’s stock, valued at $1,181,292. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Susan E. Barrowcliffe sold 18,390 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $22.00, for a total value of $404,580.00. Following the sale, the insider now directly owns 3,223 shares in the company, valued at $70,906. The disclosure for this sale can be found here. Over the last three months, insiders have sold 315,815 shares of company stock worth $8,337,379. Insiders own 17.59% of the company’s stock.
A number of research firms have recently issued reports on AIMT. Wedbush restated an “ourperform” rating and issued a $42.00 price target on shares of Aimmune Therapeutics in a research note on Monday, August 14th. BidaskClub downgraded Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Zacks Investment Research upgraded Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, October 16th. Piper Jaffray Companies set a $38.00 target price on Aimmune Therapeutics and gave the company a “buy” rating in a research report on Saturday, October 21st. Finally, Credit Suisse Group lifted their target price on Aimmune Therapeutics from $36.00 to $45.00 and gave the company an “outperform” rating in a research report on Monday, October 23rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $51.00.
WARNING: “Aimmune Therapeutics, Inc. (AIMT) Issues Quarterly Earnings Results” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/11/07/aimmune-therapeutics-inc-aimt-issues-quarterly-earnings-results.html.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Stock Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related stocks with our FREE daily email newsletter.